Page 35 - P4403.59 V47 Numark Magazine Jan PRINT
P. 35

The Power
                  of Collaboration

                Numark International Conference
                        Mykonos 2024




 FOR HEALTHCARE
 PROFESSIONALS ONLY




 Phoenix Codes   Product   Strength   Presentation   Unit of Measure

 6776744   Sertraline   150mg   tablet   30

 6776777   Sertraline   200mg   tablet   30


 Sertraline is available in two new unique   Numark International Conference 2024         th            th
                          We are hosting our biennial conference from Wednesday 5 –Sunday 9
 strengths, reducing tablet burden for patients  June 2024 in Mykonos in the Myconian Utopia Hotel, a highly regarded
                          venue with excellent facilities for our conference business sessions.
                          Networking plays a crucial role in developing and enhancing business
 Sertraline 150 mg and 200 mg film-coated tablets Prescribing Information.  monitored. Discontinue in any patient who develops seizures. Suicide/suicidal thoughts/suicide attempts or   reactions,  in  some  neonates,  whose  mothers  had  been  on  sertraline.  Sertraline  is  not  recommended  in
 See Summary of Product Characteristics (SmPC) before prescribing.  clinical worsening: Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide.   pregnancy, unless the clinical condition of the woman is such that the benefit of the treatment is expected to   relationships, and that’s why our theme for this conference is "The Power
 Presentation: Available in two strengths. Each film-coated tablet contains sertraline hydrochloride, equivalent to   Monitor patients closely until improvement occurs. The risk of suicide may increase in the early stages of   outweigh the potential risk. Neonates should be observed if maternal use of sertraline continues into the later   of Collaboration".
 150 mg or 200 mg sertraline. Indications: Treatment of major depressive episodes; prevention of recurrence of   recovery. Other psychiatric conditions can also be associated with an increased risk of suicide-related events. In   stages of pregnancy, particularly the third trimester. Epidemiological data have suggested that the use of SSRIs
 major depressive episodes; panic disorder with or without agoraphobia; obsessive compulsive disorder (OCD)   addition, these conditions may be co-morbid with major depressive disorder. Close supervision of patients   in pregnancy, particular in late pregnancy, may increase the risk of persistent pulmonary hypertension in the
 in adults and paediatric patients aged 6-17 years; social anxiety disorder; post-traumatic stress disorder (PTSD).   (particularly those at high risk, such as those with history of suicidal ideation) is advised, especially in early   newborns  (PPHN).  Lactation:  Published  data  concerning  sertraline  levels  in  breast  milk  show  that  small   The conference will focus on helping members explore ways to increase
 Dosage: For oral use. It should be administered once daily, in the morning or evening, with or without food. Initial   treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to   quantities of sertraline and its metabolite N-desmethylsertraline are excreted in milk. To date, no adverse effects
 treatment: Depression and OCD: treatment should be started at a dose of 50 mg/day. Panic Disorder, PTSD, and   monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek   on the health of infants nursed by mothers using sertraline have been reported, but a risk cannot be excluded.   operational efficiencies, develop their service portfolio, enhance
 Social Anxiety Disorder: therapy should be initiated at 25 mg/day. After one week, the dose should be increased   medical advice immediately if these symptoms present. Paediatric population: Not to be used in the treatment of   Use in nursing mothers is not recommended unless, in the judgment of the physician, the benefit outweighs the
 to 50 mg once daily. This dosage regimen has been shown to reduce the frequency of early treatment emergent   children and adolescents under the age of 18 years, except for patients with obsessive compulsive disorder aged   risk. Effects on ability to drive and use machines: Sertraline has no effect on psychomotor performance,   purchasing potential, and drive profitability.
 side effects characteristic of panic disorder. Titration: Depression, OCD, Panic Disorder, Social Anxiety Disorder   6-17 years old. Suicide-related behaviours and hostility have been more frequently observed among children   however, as psychotropic drugs may impair mental/physical abilities required driving or operating machinery,
 and PTSD: Patients not responding to a 50 mg dose may benefit from dose increases. Dose changes should be   and adolescents treated with antidepressants. Patients should be carefully monitored for appearance of suicidal   patients should be cautioned accordingly. Undesirable effects: Refer to SmPC for full information. Very   In addition to our business sessions, the conference will also provide an
 made in steps of 50 mg at intervals of at least one week, up to a maximum of 200 mg/day. Changes in dose   symptoms. Monitor paediatric patients on long term treatment for abnormalities in growth and development.   Common  (≥1/10):  Insomnia,  dizziness,  headache,  somnolence,  nausea,  diarrhoea,  dry  mouth,  ejaculation
 should not be made more frequently than once per week given the 24-hour elimination half-life of sertraline. The   Abnormal bleeding/Haemorrhage: Caution is advised in patients taking SSRIs, particularly in concomitant use   failure,  fatigue.  Common  (≥1/100  to  <1/10):  upper  respiratory  tract  infection,  pharyngitis,  rhinitis.  anxiety,   opportunity for our members to engage with both their peers and senior
 onset  of  therapeutic  effect  may  be  seen  within  7  days.  However,  longer  periods  are  usually  necessary  to   with  drugs  known  to  affect  platelet  function,  as  well  as  in  patients  with  a  history  of  bleeding  disorders.   depression, agitation, decreased libido, nervousness, depersonalisation, nightmare, bruxism, tremor, movement
 demonstrate therapeutic response, especially in OCD. Maintenance: Dosage during long-term therapy should   Hyponatraemia: Hyponatraemia may occur as a result of treatment with SSRIs or SNRIs including sertraline.   disorders (including extrapyramidal symptoms), paraesthesia, hypertonia, disturbance in attention, dysgeusia,   management from Numark and PHOENIX. This will help them gain insight
 be  kept  at  the  lowest  effective  level,  with  subsequent  adjustment  depending  on  therapeutic  response.   Elderly patients and those taking diuretics/otherwise volume-depleted may be at greater risk. Discontinuation of   visual disturbance, tinnitus, palpitations, hot flush, yawning, dyspepsia, constipation, abdominal pain, vomiting,
 Depression: Longer-term treatment may also be appropriate for prevention of recurrence of major depressive   sertraline  should  be  considered  in  patients  with  symptomatic  hyponatraemia  and  appropriate  medical   flatulence,  hyperhidrosis,  rash,  back  pain,  arthralgia,  myalgia,  irregular  menstruation,  erectile  dysfunction,   into the outlook and strategy for pharmacy in the future.
 episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence of MDE is the same   intervention  should  be  instituted.  Withdrawal symptoms  seen on discontinuation  of sertraline  treatment:   malaise, chest pain, asthenia, pyrexia, increased weight, injury. Withdrawal symptoms seen on discontinuation
 as the one used during current episode. Patients with depression should be treated for at least 6 months to   Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt. It is   of sertraline treatment: Discontinuation of sertraline (particularly when abrupt) commonly leads to withdrawal
 ensure they are free from symptoms. Panic disorder and OCD: Continued treatment in panic disorder and OCD   advised that sertraline should be gradually tapered when discontinuing treatment over a period of several weeks   symptoms. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia   The cost per delegate is £3,499, places are extremely limited so book
 should be evaluated regularly, as relapse prevention has not been shown for these disorders. Elderly patients:   or months, according to the patient’s needs. Akathisia/psychomotor restlessness: The use of sertraline has been   and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly   early to avoid disappointment.
 should be dosed carefully, as elderly may be more at risk for hyponatraemia. Patients with hepatic impairment:   associated  with  the  development  of  akathisia,  characterised  by  a  subjectively  unpleasant  or  distressing   reported effects. Generally, these events are mild to moderate and are self-limiting; however, in some patients
 approached with caution. A lower or less frequent dose should be used. Sertraline should not be used in cases   restlessness and need to move often accompanied by an inability to sit or stand still. In patients who develop   they may be severe and/or prolonged. It is advised that when sertraline treatment is no longer required, gradual
 of severe hepatic impairment as no clinical data are available. Patients with renal impairment: No dosage   these symptoms, increasing the dose may be detrimental. Hepatic impairment: If sertraline is administered to   discontinuation by dose tapering should be carried out. Elderly population: SSRIs or SNRIs including sertraline
 adjustment is necessary. Paediatric population: Children and adolescents with OCD: Age 13-17 years: Initially   patients with hepatic impairment, a lower or less frequent dose should be considered. Do not be use in patients   have been associated with cases of clinically significant hyponatraemia in elderly patients, who may be at
 50 mg once daily. Age 6-12 years: Initially 25 mg once daily. The dosage may be increased to 50 mg once daily   with severe hepatic impairment.  Renal impairment:  Sertraline  is  extensively  metabolised,  and  excretion  of   greater risk for this adverse event. Paediatric population: Very common (≥1/10): Headache (22%), insomnia
 after one week. Subsequent doses may be increased in case of less than desired response in 50 mg increments   unchanged drug in urine is a minor route of elimination. Dosing does not have to be adjusted based on the   (21%), diarrhoea (11%) and nausea (15%). Common (≥1/100 to <1/10): Chest pain, mania, pyrexia, vomiting,
 over a period of some weeks, as needed. The maximum dosage is 200 mg daily. The generally lower body   degree of renal impairment. Use in elderly: SSRIs or SNRIs including sertraline have been associated with cases   anorexia, affect lability, aggression, agitation, nervousness, disturbance in attention, dizziness, hyperkinesia,
 weights of children compared to those of adults should be taken into consideration when increasing the dose   of clinically significant hyponatraemia in elderly patients, who may be at greater risk for this adverse event.   migraine,  somnolence,  tremor,  visual  disturbance,  dry  mouth,  dyspepsia,  nightmare,  fatigue,  urinary   Call 0800 783 5709
 from 50 mg. Dose changes should not occur at intervals of less than one week. Efficacy is not shown in   Diabetes: In patients with diabetes, treatment with an SSRI may alter glycaemic control. Insulin and/or oral   incontinence, rash, acne, epistaxis, flatulence. Uncommon (≥1/1000 to <1/100): ECG QT prolonged, suicide
 paediatric  major  depressive  disorder.  No  data  are  available  for  children  under  6  years  of  age.  Withdrawal   hypoglycaemic  dosage  may  need  to  be  adjusted.  Electroconvulsive therapy:  There  are  no  clinical  studies   attempt, etc. Class effects: Epidemiological studies, mainly conducted in patients 50 years of age and older,
 symptoms seen on discontinuation of sertraline: Abrupt discontinuation should be avoided. When stopping   establishing the risks or benefits of the combined use of ECT and sertraline. Grapefruit juice: The administration   show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this
 treatment with sertraline the dose should be gradually reduced over a period of at least one to two weeks in order   of sertraline with grapefruit juice is not recommended. Interference with urine screening tests: False-positive   risk is unknown. Overdose: See SmPC for management guidance. Marketing Authorisation number and   for more information or
 to reduce the risk of withdrawal reactions. If intolerable symptoms occur following a decrease in the dose or upon   urine  immunoassay  screening  tests  for  benzodiazepines  have  been  reported  in  patients  taking  sertraline.   Basic NHS Price: Both strengths sold in packs of 30. Sertraline 150 mg PL 01883/0364 - £13.50; Sertraline 200
 discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently,   Confirmatory  tests,  such  as  gas  chromatography/mass  spectrometry,  will  distinguish  sertraline  from   mg PL 01883/0365 - £18.00. Marketing Authorisation Holder: Macarthys laboratories Limited, T/A Martindale
 the  physician  may  continue  decreasing  the  dose,  but  at  a  more  gradual  rate.  Contraindications:   benzodiazepines. Angle-Closure glaucoma: Sertraline should therefore be used with caution in patients with   Pharma, Bampton Road, Harold Hill, Romford, Essex, RM3 8UG, United Kingdom. Legal Category: POM.   register your place by
 Hypersensitivity  to  the  active  substance  or  any  of  the  excipients.  Concomitant  treatment  with  irreversible   angle-closure glaucoma or history of glaucoma. Sertraline contains Lactose Monohydrate: Patients with rare   Further information: Martindale Pharma, Bampton Road, Romford, RM3 8UG. Tel: 01277 266 600. Date of
 monoamine oxidase inhibitors (MAOIs) due to the risk of serotonin syndrome with symptoms such as agitation,   hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should   Preparation: 20th March 2023. Job Bag Number: UK-SER-2
 tremor and hyperthermia. Sertraline must not be initiated for at least 14 days after discontinuation of treatment   not take sertraline. Sexual dysfunction: SSRIs may cause symptoms of sexual dysfunction. Interactions: Refer   scanning the QR code:
 with an irreversible MAOI. Sertraline must be discontinued for at least 7 days before starting treatment with an   to SmPC for full details. Sertraline interacts with the following medicinal products: MAOIs; Pimozide; CNS
 irreversible MAOI. Concomitant intake of pimozide is contraindicated. Precautions and Warnings: Please   depressants and alcohol; Other serotonergic drugs; fentanyl and other opiate drugs; drugs that prolong the QT
 consult SmPC for full details. Serotonin Syndrome (SS) or Neuroleptic Malignant Syndrome (NMS): Monitor   Interval;  lithium;  phenytoin;  warfarin;  digoxin;  atenolol;  cimetidine;  drugs  affecting  platelet  function;   Adverse events should be reported. Reporting forms and
 for the emergence of signs and symptoms of SS or NMS syndrome. Switching from SSRIs, antidepressants or   neuromuscular blockers. Triptans: Symptoms of serotonergic syndrome may occur; Rare post-marketing reports
 anti-obsessional drugs: Care and prudent medical judgment should be exercised when switching, particularly   describe  weakness,  hyperreflexia,  incoordination,  confusion,  anxiety  and  agitation  following  use  with   information can be found at https://yellowcard.mhra.gov.uk/
 from long-acting agents such as fluoxetine. Other serotonergic drugs e.g. tryptophan, fenfluramine and 5-HT   sumatriptan. CYP3A4 Inducers: It cannot be excluded that CYP3A4 inducers and inhibitors affect sertraline   or search for MHRA Yellow Card in the Google Play or Apple App
 agonists:  Co-administration  with  other  drugs  which  enhance  the  effects  of  serotonergic  neurotransmission   plasma  levels.  Avoid  potent  CYP3A4  inhibitors.  Drugs  Metabolized  by  Cytochrome  P450:  Mild-moderate
 should be undertaken with caution and avoided whenever possible. QTc Prolongation/Torsade de Pointes: Use   inhibitor  of  CYP2D6.  Sertraline  does  not  inhibit  CYP3A4,  CYP2C9,  CYP2C19  and  CYP1A2  to  a  clinically   Store. Adverse events should also be reported to
 with caution in patients with additional risk factors for QTc prolongation such as cardiac disease, hypokalaemia   significant  degree.  Grapefruit juice:  avoid.  Sertraline  plasma  levels  are  enhanced  by  about  50%  in  poor   Martindale Pharma, an Ethypharm Group Company.
 or hypomagnesemia, familial history of QTc prolongation, bradycardia and concomitant use of medications which   metabolizers of CYP2C19 compared to rapid metabolizers. Interaction with strong inhibitors of CYP2C19 cannot   Tel: 01277 266 600.
 prolong QTc interval. Activation of hypomania or mania: Use with caution in patients with a history of mania/  be excluded. Fertility, pregnancy and lactation. Fertility: No impact shown on animal fertility. Impact on human
 hypomania. Close surveillance by the physician is required. Discontinued in patients entering a manic phase.   fertility has not been observed so far. Pregnancy: There are no well controlled studies in pregnant women.   e-mail: drugsafety.uk@ethypharm.com
 Schizophrenia: Psychotic symptoms might become aggravated in schizophrenic patients. Seizures: Seizures   However, a substantial amount of data did not reveal evidence of induction of congenital malformations by
 may occur: avoid in patients with unstable epilepsy and patients with controlled epilepsy should be carefully   sertraline. Use of sertraline during pregnancy has been reported to cause symptoms, compatible with withdrawal
 Date of preparation: September 2023   UK-SER-4a                                                                  35
                                                                                                                 12/12/2023   14:40:25
         P4403.59 V47 Numark Magazine Jan 24.indd   35
         P4403.59 V47 Numark Magazine Jan 24.indd   35                                                           12/12/2023   14:40:25
   30   31   32   33   34   35   36